» Articles » PMID: 32544462

PADI4 Modulates the Invasion and Migration of Osteosarcoma Cells by Down-regulation of Epithelial-mesenchymal Transition

Overview
Journal Life Sci
Publisher Elsevier
Date 2020 Jun 17
PMID 32544462
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma (OS) is the most common type of primary bone malignancy with high recurrence and metastasis. Peptidylarginine deiminase 4 (PADI4), as an important protein post-translational modification enzyme, has been identified as a potential regulator in the invasion and migration in several types of tumors. The role of PADI4 in osteosarcoma metastasis remains unknown. In this study, we revealed significant positive correlation between PADI4 and pulmonary metastasis of osteosarcoma. Wound-healing and transwell assay indicated that PADI4 induced invasion and migration of osteosarcoma cell in vitro while PADI4 inhibitor has repressive effect. PADI4 mutation with no deimination activity exhibited no significant effect on invasion and migration of osteosarcoma cells. Moreover, we evaluated the effect of PADI4 on expression of the markers of epithelial-mesenchymal transition and results showed that PADI4 promoted EMT while PADI4 inhibitor suppressed EMT in osteosarcoma cells. We also detected the expression of PADI4 and E-Cadherin in the tissues of osteosarcoma patients with or without pulmonary metastasis. Results showed positive relationship between the expression of PADI4 and osteosarcoma metastasis. In contrast, the expression of E-Cadherin exhibited negative correlation with PADI4 and osteosarcoma metastasis. Our research offered a novel link between PADI4 and osteosarcoma metastasis and demonstrated PADI4 as a promising target for treatment of osteosarcoma metastasis.

Citing Articles

Targeting PADI2 as a potential therapeutic strategy against metastasis in oral cancer via suppressing EMT-mediated migration and invasion and CCL3/5-induced angiogenesis.

Hung S, Yu C, Lin H, Chiou W, Lee M, Lin R Clin Exp Metastasis. 2024; 41(6):925-935.

PMID: 39215870 DOI: 10.1007/s10585-024-10310-5.


Investigating the cell membrane localization of PADI4 in breast cancer cells and inhibition of anti-PADI4 monoclonal antibody.

Wang Y, Song X, Song Y, Fang K, Chang X J Cancer Res Clin Oncol. 2023; 149(19):17253-17268.

PMID: 37804426 PMC: 10657297. DOI: 10.1007/s00432-023-05433-3.


Regulation of the Epithelial to Mesenchymal Transition in Osteosarcoma.

Hinton K, Kirk A, Paul P, Persad S Biomolecules. 2023; 13(2).

PMID: 36830767 PMC: 9953423. DOI: 10.3390/biom13020398.


PAD4 and Its Inhibitors in Cancer Progression and Prognosis.

Zhu D, Lu Y, Wang Y, Wang Y Pharmaceutics. 2022; 14(11).

PMID: 36365233 PMC: 9699117. DOI: 10.3390/pharmaceutics14112414.


PAD4-dependent citrullination of nuclear translocation of GSK3β promotes colorectal cancer progression via the degradation of nuclear CDKN1A.

Luo X, Chang S, Xiao S, Peng Y, Gao Y, Hu F Neoplasia. 2022; 33:100835.

PMID: 36113195 PMC: 9483803. DOI: 10.1016/j.neo.2022.100835.